Developing an Evidence-Based Epilepsy Risk Assessment eHealth Solution: From Concept to Market by Newman, C et al.
Original Paper
Developing an Evidence-Based Epilepsy Risk Assessment eHealth
Solution: From Concept to Market
Craig Newman1, BSc (Hons), PhD, DClinPsy; Rohit Shankar2, MBBS, MRCPsych; Jane Hanna3; Brendan McLean4,
PhD, FRCP; Alex Osland3; Cathryn Milligan5; Abbie Ball5; Caryn Jory6; Matthew Walker7, PhD, FRCP
1Neuro-Cognitive Research Group (NeuroCoRe), Plymouth University Peninsular School of Medicine and Dentistry (PUPSMD), Plymouth, United
Kingdom
2Exeter Medical School, Exeter, United Kingdom
3SUDEP Action, Oxfordshire, United Kingdom
4Royal Cornwall Hospital Trust, Truro, United Kingdom
5Neuro-Cogntivie Research Group (NeuroCoRe), Plymouth University Peninsular School of Medicine and Dentistry (PUPSMD), Plymouth, United
Kingdom
6Cornwall Partnership NHS Foundation Trust, Bodmin, United Kingdom
7UCL Institute of Neurology, London, United Kingdom
Corresponding Author:
Craig Newman, BSc (Hons), PhD, DClinPsy
Neuro-Cognitive Research Group (NeuroCoRe)
Plymouth University Peninsular School of Medicine and Dentistry (PUPSMD)
N13 ITTC Building
Plymouth Science Park,
Plymouth, PL6 8BX
United Kingdom
Phone: 44 1752315264
Fax: 44 1752792560
Email: craig.newman@plymouth.ac.uk
Abstract
Introduction: Sudden unexpected death in epilepsy (SUDEP) is possibly the most common cause of death as a result of
complications from epilepsy. The need to educate and regularly review risk for all patients with epilepsy is paramount, but rarely
delivered in actual clinical practice. Evidence suggests that education around SUDEP and modifiable risk variables translate into
better self-management of epilepsy.
Objective: We aimed to develop and implement an eHealth solution to support education and self-management of risks, in
epilepsy.
Methods: We undertook an innovation pathways approach, including problem identification, feasibility assessment, design,
implementation, and marketing. People with epilepsy were provided a smartphone-based app (Epilepsy Self-Monitor, EpSMon),
which translates the clinical risk assessment tool into an educational and self-monitoring platform, for the self-management of
epilepsy.
Results: Results include the success of the marketing campaign, and in what areas, with an estimated reach of approximately
38 million people. EpSMon has proved a success in academic and clinical circles, attracting awards and nominations for awards.
The number of users of EpSMon, after 3 months, turned out to be lower than expected (N=221). A 4-month trial of the app in
use in the United Kingdom, and the success of the marketing strategy, point to necessary changes to the model of delivery and
marketing, summarized in this paper. These include the marketing message, user cost model, and need for the availability of an
Android version.
Conclusions: EpSMon has proven a success in respect to its reception by academics, clinicians, stakeholder groups, and the
patients who use it. There is work needed to promote the model and increase its acceptability/attractiveness, including broadening
the marketing message, increasing its availability, and reducing its cost. Future development and promotion of the tool will
hopefully inform iterative design of its core features for a receptive audience and lead to increased uptake as it is launched
worldwide in 2016.
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Introduction
Background
Epilepsy is one of the most common neurological disorders
globally affecting 5 to 40 people per 1000 population [1].
Epilepsy affects approximately 50 million people throughout
the world. It has been estimated that 10% of the burden of brain
and mental disorders in the world is caused by epilepsy. This
calculation includes premature deaths and the loss of healthy
life due to disability [2].
Sudden unexpected death in epilepsy (SUDEP) is the most
important direct epilepsy-related cause of death [3]. SUDEP is
possibly the most common cause of death as a result of
complications from epilepsy, accounting for between 7.5% and
17% of all epilepsy-related deaths and [4] 50% of all deaths in
refractory epilepsy [5]. Sudden death is 20 times higher in
people with epilepsy (PWE) than the general population.
Epilepsy is the 5th highest cause of life-years lost and the public
health burden of SUDEP alone is estimated as second only to
stroke among neurological conditions [6]. Forty-two percent of
all deaths are considered avoidable [7]. Consequently, the
National Institute for Health and Care Excellence epilepsy
guidelines 2004 and 2012 [8] recommend discussion of SUDEP
with newly diagnosed PWE. This is rarely delivered and until
recently only 4% of PWE had a recorded SUDEP discussion
[9].
There is robust evidence to suggest that knowledge relating to
modifiable risk factors would help empower the patient to take
responsibility toward his well-being in managing his condition
[10-12]. Recent studies have shown that factors influencing
SUDEP and other direct causes of epilepsy death overlap
[13-15].
Aim
Development of a patient-centered eHealth solution to reduce
risk of SUDEP and educate PWE around risk. Utilization of
quality improvement and iterative cycles of development to
evidence the proposed solution.
Methods
App Conceptualization
In the conceptualization stage of a patient-administered eHealth
alternative to the consultant-administered checklist, it was
important to identify how this might fit alongside existing care
pathways and where, if anywhere, a clear gap in service delivery
was observed. Consultation was undertaken with a specialist
national Epilepsy charity (SUDEP Action), a specialist general
practitioner (GP) commissioning group in Cornwall, UK and
both national academic and consultant specialists in epilepsy.
This steering group identified the removal of the primary
care–based Quality Outcomes Framework financial support for
annual epilepsy reviews, provided by GPs, would likely translate
into a significant reduction in epilepsy reviews in the community
for patients not identified as at risk. A service pathway was
drafted, which included an eHealth self-monitoring option, for
patients to self-administer, which could act as a triaging tool
alongside existing primary care models.
Stepped-Care Model Approach
A rapid informal review of eHealth solutions delivered in other
sectors revealed a range of options for support, including general
education, risk-specific educational interventions, prompts to
seek help, and automated triggering of community or secondary
care service support. Against the current level of support for
PWE with ongoing seizures, where it is currently their own
responsibility to seek help when they perceive a need, the
steering group perceived that support in the ability to identify
when this need is present was most relevant. This is reinforced
by earlier reported findings [16] in which coroner data for
SUDEP-related deaths identified that only 20% of patients had
sought medical contact with an epilepsy specialist in the period
of 12 months prior to their deaths. The evidence indicated a
3-month high-risk period for people whose risk profile
deteriorates, as identified by the checklist, and so the identified
eHealth need was the provision of an informative risk
assessment at prompted 3-monthly intervals.
Technology Identification
The steering group assessed the potential risks and benefits of
differing technologies to support this eHealth solution, including
a systematic review of existing seizure detection methods [17].
Primarily, the goals of the project required ease of use,
accessibility, effortless international dissemination, notification
capabilities, and data collection capabilities (to support the
ongoing development of the checklist). A mobile app was
selected due to the ongoing surge of take-up of these devices
(6.9 billion mobile phone prescriptions worldwide with a
forecast of 5.6 billion smartphone subscriptions by 2019, Global
mobile statistics report - 2014 [18]), the tendency for owners
to carry their device at all times, the numerous notification
options and the expansive range of data collection options
including take-up and user retention data.
App Design (EpSMon – Epilepsy Self Monitor)
The development of the App content was iterative, cycling on
the basis of specialist input across a range of development
themes: the consultant steering group, a patient-representative
group (recruited by the charity), University information
technology (IT) support services and patients of volunteer
clinicians were repeatedly involved in providing feedback across
a range of development stages, (summarized in Figure 1)
A wire-frame (flowchart of screens, features, and server activity)
was initially developed by a local University-based team who
specialize in the development of apps for neurology and clinical
services. Following this, a graphical representation mock-up
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was produced providing, first versions of the graphics in situ in
a functioning App and the final Beta version prerelease (a Beta
version being the version that is tested for coding bugs, all other
features assumed complete). The target users for this tool span
all ages and demographics and so the development team strived
to access a diverse feedback group.
Usability testing (public and patient involvement, PPI): explored
and observed how users experienced and used the app naturally
and across a series of identified tasks. This research was led
independently by the charity (to be published separately),
software team, and specialist clinicians in clinics with patients.
Feedback was reviewed by the steering committee with design
modifications to the app when deemed appropriate.
In order to generate the content of the app, the translation of the
checklist into a self-administered tool, supported by educational
material, was led by the charity in liaison with a specialist patient
consultation group and specialist clinicians and academics in
this field. This content was reviewed in the first version of the
app, by volunteer patient representatives, with edit
recommendations made when deemed appropriate by the
steering committee. The steering committee decided upon a
minimum governance standard for the project, requiring that
the checklist be taken through an annual update, requiring
ongoing reviews of the literature. An update cycle was
undertaken during the build of the app and the app content was
updated accordingly.
Once version 1 of the app was built, beta testing was completed
for bugs in its functioning by all supporting partners, and a range
of patient representatives who had registered to support this
activity on a prerelease invitation hosted on the charity’s
website. Prior to release of the app to iTunes, the app’s code,
user policies, terms of use, data protection protocols, and
security protocols (data encryption, secure transfer, etc) were
all reviewed by an IT specialist and legal services provided by
the University partner.
Given the heterogeneous characteristics of the potential user
population, being any individual with epilepsy and so any age,
sex, or race – speculations about user preference or accessibility
to devices seemed uninformative beyond national update
statistics. Rather, it was decided to aim to release the app to the
most popular platforms (Apple and Android) with the aspiration
to expand to provide to Windows phones if resources allow.
Key Feature Selection
Following the iterative design process, the app was completed
with a range of features that are supportive to patients, service
delivery and future research. The features included represent
the minimum required to rapidly meet identified user needs and
research model of the project, with additional features to be
considered in future updates.
It was considered valuable to develop capability to support users
in self-triaging their need to seek clinical contact, following an
assessment of risk. The translation of the checklist into a
self-assessment provides a robust evidence-based self-triaging
tool that identifies risk change across regular time intervals.
Rather than providing a binary health care approach, a
stepped-care approach was designed into the app. EpSMon
initially educates PWE around variables related to risk through
regular exposure to the checklist. Secondly, succinct educational
content is provided to support further queries around identified
risk with the app designed to encourage access to this
information. Finally, the app encourages contact with a GP
when appropriate and queries whether this was adhered to at
the next assessment. As an additional safety precaution, a
telephone number is provided for people who are distressed or
confused, direct to SUDEP Action.
Interventions in other disease areas frequently use a stratified
approach, cutting off access to services at a particular percentage
of risk of serious disease or death. The Checklist and EpSMon
do not do this. The app replicates the checklist, in that it is
designed to not include a cumulative score or percentage of risk
so there is no cut off of risk, hopefully maximizing doctor and
patient empowerment and risk-management. To maintain a
quality risk-management and clinical governance approach, the
app is designed to support research by consenting users into
research and collecting data relating to user demographics,
comorbidity, medication use (epilepsy, depression, and
psychosis), risk profiles over time, and app usage.
App Governance
After reviewing the government’s criteria for app medical device
registration [19], it was considered that EpSMon does not meet
entry requirements. EpSMon does not diagnose, monitor,
prevent, treat, or alleviate a disease. Although the tool is called
a monitor, this is a reference to the tool supporting the self-report
of user’s perceptions about their current state that is used to
prompt education or conversation with a clinician, no raw data
is interpolated for clinical use. The app is not an alternative to
standard treatment and nor does it interfere with or recommend
any treatment plan, which is a stipulation (not met) for medical
device status required by the Medicines and Healthcare products
Regulatory Agency. It informs its users that the results are not
to be considered as anything but suggestive. This position could
change if the underlying questionnaire responses are developed
into statistically weighted factors and the report process becomes
more interpretative. This may also need further consideration
when EpSMon is released to other countries, such as the United
States.
While the safety checklist was developed for SUDEP, risk
factors such as nonadherence and depression are relevant to
epilepsy mortality generally. They bring a set of questions to
the fingertips of doctors and patients that were developed from
research on SUDEP. Many of the questions overlap with
epilepsy mortality generally and the 2015 version of the
Checklist agreed by a UK development group of experts includes
the latest research on epilepsy fatality. These include questions
on wellbeing as well as seizures.  The Checklist will be reviewed
annually to enable updating with evidence on fatality. A question
on comorbidity has already been identified as an area for
recommended inclusion in 2017.  Country versions outside the
United Kingdom will need additional information and country
contextualization if there are no national guidelines in place.
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Figure 1. Cycles of iterative development undertaken in creating EpSMon.
Results
Launching the Epilepsy Self-Monitor App
EpSMon was launched to iPhone (UK only) in July 2015 at a
cost of £1.49 for life-time access. A strategic marketing
communications campaign supported the launch of the app,
with public relations support from all partner organizations.
Coverage achievements included 5× regional television news
reports (audience estimates unavailable), 7× regional radio
reports (estimated 1.5 million audience), 27× national and
regional newspaper articles (estimated 33.2 million audience),
625 Facebook likes, 424 shares, and 255 clicks to the website
(from a potential Facebook reach of 360, 000) and 110,300
‘EpSMon’ retweets and 14,900 mentions. In total, the marketing
communications campaign attained an overall reach of
approximately 38 million people.
A full-time support phone line was indicated in the app, provided
by SUDEP Action. Very little activity has been generated, with
contact mostly relating to enquiries for an Android version of
the tool.
Releasing EpSMon has been a very positive experience with
unanimous support from clinicians, academics, and patients
who have had contact. It has received awards at the International
League Against Epilepsy conference, mass media interest, and
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two nominations to the Health Service Journal Innovation
awards (HSJ) despite its infancy in respect to project duration.
The almost nonexistent need for support, by users, encourages
further expansion of the user base.
Since the launch, 221 users have downloaded the tool and
registered, with 218 having assessed their risk. In addition,
EpSMon has also been adopted into the National Epilepsy
Commissioning Toolkit, alongside its parent checklist for
clinicians. The app collects, with consent, users’ age, sex,
epilepsy diagnosis duration, seizure type, medications use,
questionnaire responses, and app-use frequency data for all
users. This data will be used to both better understand the
existing user base, for purposes of further project delivery, and
to support the research that will further develop the risk
checklist’s ongoing development.
APP Modifications
The current user base, while modest, represents a test base for
the project and has supported the identification of areas in which
further work is needed. The first of these is cost. The
introduction of a £1.49 fee was driven by a desire to test whether
this would increase trust in the product, rather than a need to
fund the project. Data indicates that 80% of visitors to the app
download page do not purchase the app, which may be a
consequence of this fee structure. The steering committee has
chosen to remove this fee and to provide the app at no cost. This
may, in addition, encourage GPs and other organizations to
promote the tool without fear that there is a profit motive for
the partners involved.
There is an imminent need to provide an Android version of the
tool, based on feedback to the charity and the fact that 79% of
smartphone ownership is Android [20]. This could translate into
an immediate rapid uptake of EpSMon, especially in the context
of this being provided at no cost.
The marketing campaign for EpSMon was built on earlier
epilepsy work relating to safety, ‘Safety in your pocket.’
 Feedback since the launch suggests that we may need to
consider a multipronged approach.  Marketing strategies are
currently being explored, with potential but resistant users. A
second marketing communications campaign is planned for mid
2016, with news of the app now being free and available for
Android and new Apple users. 
Discussions are underway with potential US supporters who
can provide marketing support into a US market in early 2016.
This will involve the bundling of a Spanish translation of the
tool. A translation proforma has been developed, which will be
provided to a translation agency in the near future.
Discussion
Principal Findings
The development of EpSMon and its first phase of
implementation has been successful. In only 4 months the tool
has been adopted into the commissioning toolkit for the National
Health Service and has been nominated as a finalist in two
categories of the UK’s prestigious HSJ. The project has also
received recent prizes at the International League Against
Epilepsy for best poster and best presentation. The reception
from academics, clinicians, families, and users is to date
unanimously positive and supportive.
The take up of the app has been modest, although this likely
reflects a cocktail of challenges that will require a responsive
and reflective approach, beyond the need for an Android version
summarized above. The literature relating to SUDEP in many
ways characterizes both community and clinical level denial or
ignorance as to the need to monitor risk of death in PWE.
Marketing to a potential user base who are unaware of, or
disconnect from, the narrative of risk in epilepsy is a challenge.
The EpSMon project will seek to engage with clinicians, who
already appear very receptive, and user groups to develop
marketing strategies that engage people in the community, GPs,
and specialist clinicians. In addition, work is underway to embed
EpSMon into standard advice practice of GPs, through research
trials to demonstrate the efficacy of this approach and specialist
GP e-training (expected implementation in spring 2016).
Conclusions
Although this project appears U-centric, SUDEP is a global
phenomenon. There is a higher prevalence of epilepsy in
economically poorer and developing countries than economically
developed countries [21]. In such poor countries, priority of
safety and ignorance is rife. Presence of a cost-effective solution
such as the app could save lives. The initiative toward making
this app free to use, and housed within a research collaborative
model, will hopefully invite opportunities to create impact in
these contexts, through further development and uptake of
EpSMon. Further usability research, academic publication of
the tool’s merits, and developments alongside a strong research
strategy will hopefully further support the success of this project
into the future and beyond the United Kingdom.
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